Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Healing & Recovery
Gastric pentadecapeptide with broad tissue-healing properties.
Peptide B
Healing & Recovery
Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity.
Typical vial
5 mg
Typical dose
250-500 mcg
Half-life
~4 hours (estimated from animal pharmacokinetic data)
FDA status
Not FDA approved for human use. FDA issued a warning letter …
Typical vial
5 mg
Typical dose
50-200 (intranasal) mcg
Half-life
~2 minutes (plasma); longer functional duration via tissue distribution
FDA status
Not FDA approved as therapeutic. VIP analog aviptadil receiv…
BPC-157 effects
VIP (Vasoactive Intestinal Peptide) effects
BPC-157 side effects
VIP (Vasoactive Intestinal Peptide) side effects
BPC-157 dosing ranges
General tissue repair
250-500 mcg · Once or twice daily · 4-6 weeks
Gut healing
250-500 mcg · Twice daily (oral or SubQ) · 4-8 weeks
Acute injury recovery
500 mcg · Twice daily near injury site · 2-4 weeks
VIP (Vasoactive Intestinal Peptide) dosing ranges
Intranasal CIRS protocol (off-label)
50 mcg · 4 sprays daily · Per Shoemaker protocol; months to years for full restoration
Research / immunomodulation
Variable per protocol · Per protocol · Per protocol
BPC-157: Gastric pentadecapeptide with broad tissue-healing properties. Typical dose 250-500 mcg. VIP (Vasoactive Intestinal Peptide): Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity. Typical dose 50-200 (intranasal) mcg. Both fall under the Healing & Recovery category.
Stacking BPC-157 with VIP (Vasoactive Intestinal Peptide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
BPC-157 is typically dosed: Once or twice daily for General tissue repair; Twice daily (oral or SubQ) for Gut healing; Twice daily near injury site for Acute injury recovery. VIP (Vasoactive Intestinal Peptide) is typically dosed: 4 sprays daily for Intranasal CIRS protocol (off-label); Per protocol for Research / immunomodulation.
BPC-157: Not FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products. VIP (Vasoactive Intestinal Peptide): Not FDA approved as therapeutic. VIP analog aviptadil received Emergency Use Authorization consideration for COVID-19 ARDS but not full approval.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free